Monday, January 23, 2017 9:10:15 AM
Jan. 23, 2017 6:37 AM ET|5 comments| About: Bristol-Myers Squibb Company (BMY), Includes: AGN, MRK, PFE, WBA
Summary
BMY has an activist shareholder.
But the big question is whether JANA Partners will step up and push for change.
And there are catalysts JANA can force, from a buyout to a spin off.
Bristol Myers (NYSE:BMY), the $100 billion market cap drug maker now calls billionaire activist Barry Rosenstein of JANA Partners as a shareholder. Per JANA's fourth quarter investor letter, it has made Bristol-Myers a top holding. Although it hasn't waged a 'full blown' activist campaign, it could be working behind the scenes. Plus, JANA is no stranger to waging proxy battles to force change. And there's plenty of 'change' opportunities at Bristol-Myers. The stock is down 20% over the last year and trading at 52-week lows. This comes after its immuno-oncology drug Opdivo failed to meet a Phase II trial, and Merck (NYSE:MRK) grabbed some market share. Still, Bristol-Myers has a huge opportunity with Opdivo - which is expected to become one of the best selling drugs in the world and move from sales of just $1 billion to over $13 billion in a few years.
Opdivo, which is being heavily advertised in the media, had sales near $1 billion in 2015, but analysts predict it could go much, much higher, hitting nearly $13 billion annually within a few years. Despite that failure, Opdivo is in more than 50 clinical trials, which means the drug could become one of the best-selling drugs in the world.
Be on the lookout for JANA to step it up over the next couple weeks, if they plan to push for management and board change - where the board nominee deadline for Bristol-Myers hits Feb. 2. JANA did effectively just end its campaign at Walgreens (NASDAQ:WBA) recently and is likely on the hunt for a new target. Yet, it's more likely that JANA stays in the shadows for now, seeing how Bristol-Myers progresses over the next few months. In all likelihood, JANA will want to stay constructive with these holding, offering positive feedback and possible theses for unlocking value.
The key play is to convince Bristol-Myers to diversify a bit, and take away its reliance on cancer drug Opdivo. The answer to that is acquisitions, although I'm not a huge fan of forced acquisitions. The other - and more likely - diversification answer is to merge with another major pharma company. Major mergers should be a key theme for 2017 (thanks to Donald Trump's de-regulation plans) and pharma is ripe, with the likes of Pfizer (NYSE:PFE) already on the prowl - as Pfizer is looking to build its own in-house program of immuno-oncology. As well, Merck could also be a suitable buyer for Bristol-Myers - being its largest direct competitor. But Pfizer is one of the few companies with the wherewithal, and it's hungry after its planned merger with Allergan (NYSE:AGN) fell through.
In the end, Bristol-Myers is one of the more appealing healthcare stocks. It's now even more interesting with JANA Partners involved. It's not entirely cheap, which helps with getting the company overlooked. But all the better. It's still a growth story, with the best expected five year earnings growth of any major drug maker. It's a growth story with a solid 3.2% dividend yield, and with plenty of optionality in the form of JANA, spin offs or buyouts. Part of Bristol-Myers' issue is the suggested over-reliance on one key drug, but the immuno-oncology space is attractive and Bristol-Myers should attract buyers should it decide to put on the auction block.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
__________________________________________
http://seekingalpha.com/article/4038557-bristol-myers-activist-shows-finally
BMY
Recent BMY News
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis • Business Wire • 09/18/2024 10:59:00 AM
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma • Business Wire • 09/15/2024 12:55:00 PM
- Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 • Business Wire • 09/12/2024 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/10/2024 09:45:00 PM
- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms • Business Wire • 09/09/2024 10:59:00 AM
- Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research • Business Wire • 09/06/2024 11:00:00 AM
- Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) • Business Wire • 09/01/2024 07:33:00 AM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 08/27/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024 • Business Wire • 08/26/2024 10:59:00 AM
- Cruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1% • IH Market News • 08/23/2024 12:20:26 PM
- Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma • Business Wire • 08/21/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma • Business Wire • 08/19/2024 10:59:00 AM
- Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots • IH Market News • 07/30/2024 10:00:51 AM
- Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 • Business Wire • 07/26/2024 10:59:00 AM
- U.S. Index Futures Point to Higher Open, Oil Prices Down • IH Market News • 07/26/2024 10:08:50 AM
- Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates • IH Market News • 07/26/2024 09:57:38 AM
- Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma • Business Wire • 07/19/2024 10:59:00 AM
- Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day • Business Wire • 07/08/2024 10:59:00 AM
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 06/21/2024 11:30:00 PM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab • Business Wire • 06/21/2024 10:59:00 AM
- Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 • Business Wire • 06/20/2024 10:59:00 AM
- Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors • Business Wire • 06/18/2024 08:16:00 PM
- Bristol Myers Squibb Announces Dividend • Business Wire • 06/18/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors • Business Wire • 06/13/2024 08:46:00 PM
- Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial • Business Wire • 06/04/2024 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM